基于包含三维快速自旋回波T2加权采集的多参数MRI,比较放射科医生与泌尿科医生应用膀胱影像报告和数据系统对肌层浸润性膀胱癌的临床效用
本研究纳入66例经病理证实的膀胱癌患者,在经尿道膀胱肿瘤切除术前行包含3D FSE T2加权成像的多参数MRI,由2名放射科医生和2名泌尿科医生独立按VI-RADS五分法评分并与术后病理对照。结果显示读者间一致性良好至优秀(0.73-0.91),总体VI-RADS评分AUC在放射科医生为0.94和0.92、泌尿科医生为0.89和0.87,总体评分无显著差异,但泌尿科医生DCE-MRI VI-RADS评分的敏感度和特异度显著低于放射科医生。
要点
- 总体VI-RADS评分对肌层浸润性膀胱癌诊断效能高,放射科医生AUC 0.94和0.92,泌尿科医生0.89和0.87。
- 四名读者间VI-RADS评分一致性良好至优秀,加权kappa范围0.73-0.91。
- 泌尿科医生DCE-MRI VI-RADS评分的敏感度和特异度显著低于放射科医生,总体评分无显著差异。
核心结论
- 基于包含3D FSE T2加权采集的多参数MRI的VI-RADS评分,可用于放射科医生和泌尿科医生术前判断膀胱癌肌层浸润状态。
研究设计与样本
- 本研究纳入66例未经治疗、经病理证实的膀胱癌患者(男60例、女6例,平均年龄74.0岁),于2010年1月至2018年11月间在经尿道膀胱肿瘤切除术前接受包含3D FSE T2加权成像的多参数MRI。
- MRI扫描由四名独立读者(两名委员会认证放射科医生和两名委员会认证泌尿科医生)在不知晓组织病理结果的情况下按五分法VI-RADS评分,并与术后组织病理诊断比较。
- 读者间一致性采用加权kappa系数评估,诊断效能采用ROC分析和广义估计方程评估。
诊断标准与关键数值
- 病理证实非肌层浸润性膀胱癌49例(74.2%)、肌层浸润性膀胱癌17例(25.8%)。
- 所有读者两两间一致性良好至优秀,加权kappa范围0.73-0.91。
- 总体VI-RADS评分AUC在放射科医生1、放射科医生2、泌尿科医生1、泌尿科医生2分别为0.94、0.92、0.89、0.87。
- 泌尿科医生DCE-MRI VI-RADS评分的敏感度和特异度显著低于放射科医生;总体VI-RADS评分未见显著差异。
临床应用与阅片要点
- VI-RADS评分可用于放射科医生和泌尿科医生术前判断膀胱癌肌层浸润状态。
- 总体VI-RADS评分在放射科医生和泌尿科医生中诊断效能均高,部分归因于弥散加权成像对总体VI-RADS评分的主导作用。
- 本研究中四名读者采用3D FSE T2加权采集的T2WI VI-RADS评分敏感度和特异度与既往采用2D FSE T2加权采集的发表结果相似,特异度略高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the clinical utility of the Vesical Imaging-Reporting and Data System (VI-RADS) by comparing its diagnostic performance for muscle-invasive bladder cancer (MIBC) between radiologists and urologists based on multiparametric MRI, including three-dimensional (3D) fast spin-echo (FSE) T2-weighted acquisitions.
METHODS: This study included 66 treatment-naïve patients (60 men, 6 women; mean age 74.0 years) with pathologically proven bladder cancer who underwent multiparametric MRI, including 3D FSE T2-weighted imaging, before transurethral bladder tumour resection between January 2010 and November 2018. The MRI scans were categorised according to the five-point VI-RADS score by four independent readers (two board-certified radiologists and board-certified urologists each), blinded to the histopathological findings. The VI-RADS scores were compared with the postoperative histopathological diagnosis. Interobserver agreement was assessed using weighted kappa coefficients. ROC analysis and generalised estimating equations were used to evaluate the diagnostic performance.
RESULTS: Forty-nine (74.2%) and 17 (25.8%) tumours were confirmed to be non-MIBC and MIBC, respectively, based on pathological examination. The interobserver agreement was good-to-excellent between all pairs of readers (range, 0.73-0.91). The urologists' sensitivity/specificity values for DCE-MRI VI-RADS scores were significantly lower than those of radiologists. No significant differences were observed for the overall VI-RADS score. The AUC for the overall VI-RADS score was 0.94, 0.92, 0.89, and 0.87 for radiologists 1 and 2 and urologists 1 and 2, respectively.
CONCLUSIONS: The VI-RADS score, based on multiparametric MRI including 3D FSE T2-weighted acquisitions, can be useful for radiologists and urologists to determine the bladder cancer muscle invasion status preoperatively.
KEY POINTS: • VI-RADS (using multiparametric MRI including 3D FSE T2-weighted acquisitions) achieves good to excellent interobserver agreement and has similar diagnostic performance for detecting muscle invasion by both radiologists and urologists. • The diagnostic performance of the overall VI-RADS score is high for both radiologists and urologists, particularly due to the dominant effect of diffusion-weighted imaging on the overall VI-RADS score. • The sensitivity and specificity values of the T2WI VI-RADS scores for four readers in our study (using 3D FSE T2-weighted acquisitions) were similar (with slightly higher specificity values) to previously published results (using 2D FSE T2-weighted acquisitions).
引用
- Arita Y, Shigeta K, Akita H, et al. Clinical utility of the Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer between radiologists and urologists based on multiparametric MRI including 3D FSE T2-weighted acquisitions. Eur Radiol. 2020. PMID: 32829418. doi:10.1007/s00330-020-07153-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。